In contrast to targeting AFP alone on the HCC cell surface, Ma et.al proposed that an AFP/GPC-3 double antibody-labeled probe which can target AFP and GPC-3 simultaneously could potentially increase the detection rate of HCC, and improve the efficacy in detecting heterogeneous micro malignant HCC tumors. This evidence concerns the gene GPC3 and hepatocellular carcinoma.